|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Study Failed to Meet Primary Endpoint
ISS and Glass Lewis Say Approval of Biota Transaction is in Stockholders' Best Interests
NABI Biopharmaceuticals (Nasdaq:NABI) has been downgraded by TheStreet Ratings from from a hold to sell.
Shares of NABI Biopharmaceuticals (Nasdaq:NABI) were gapping down Monday morning with an open price 64.5% lower than Friday's closing price. The stock closed at $5.63 yesterday and opened today's trading at $2.
NABI Biopharmaceuticals (Nasdaq:NABI) has been downgraded by TheStreet Ratings from from a buy to hold.
Final Data Expected in Early 2012 on Vaccine to Treat Nicotine Addiction and Prevent Smoking Relapse
The following 10 biotech stocks, though exceptionally risky, are expected to double, triple or quadruple in the next 12 months.
Patent Issued for Exclusive Use of NicVAX and Related Nicotine Vaccines to Treat or Prevent Nicotine Addiction
$8 Million Payment Due from GlaxoSmithKline Biologicals
Final Data Expected in Fourth Quarter 2011 on First-in-Class Vaccine to Treat Nicotine Addiction and Prevent Smoking Relapse
Fund manager Seth Hamot analyzes Aeropostale, Nabi and BreitBurn Energy Partners and finds value and interesting behind-the-scenes action.